Lisata Therapeutics (NASDAQ: LSTA) to be acquired by Kuva Labs Lisata Therapeutics, Inc. (LSTA) announced it has entered into a binding term sheet to be acquired by privately held Kuva Labs, Inc. for $4.00 per share in cash through a tender offer, according to a...
The True Value of LM Funding America Inc. (NASDAQ: LMFA) Infrastructure-Linked Debt In capital-intensive industries such as Bitcoin mining, the quality of debt often matters more than its absolute size. The key issue is whether leverage merely supports short-term...
Tip-toeing around the issue, Novartis CEO stated that his company avoided U.S. tariffs Novartis expects to avoid exposure to U.S. tariffs by mid-2026, according to CEO Vas Narasimhan who spoke at the World Economic Forum in Davos.“We expect to be in a position...
Heading the charge, Bristol Myers Squibb appoints Harald Hampel as Senior Vice President and Worldwide Head of Medical Affairs Bristol Myers Squibb’s neuroscience strategy is being reinforced by the appointment of Harald Hampel as Senior Vice President and Worldwide...
New and improved, Johnson & Johnson's Caplyta significantly improved remission rates Johnson & Johnson’s Caplyta significantly improved remission rates in major depressive disorder when used with antidepressants, as highlighted at a major...
